David A Lipson
Overview
Explore the profile of David A Lipson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
2735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Criner G, Lipson D, Tombs L, Han M
ERJ Open Res
. 2025 Feb;
11(1).
PMID: 40008169
https://bit.ly/47KAhmK.
2.
Alberola A, Nogal N, Miranda A, Lipson D, Tombs L, Han M
Chronic Obstr Pulm Dis
. 2024 Nov;
11(6):591-603.
PMID: 39531369
Introduction: Lung physiology and chronic obstructive pulmonary disease (COPD) pathophysiology differ between sexes. This post hoc analysis investigated the InforMing the Pathway of COPD Treatment (IMPACT) trial outcomes by patient...
3.
Wade R, Martinez F, Criner G, Tombs L, Lipson D, Halpin D, et al.
Eur Respir J
. 2024 Oct;
65(2).
PMID: 39467609
Background: COPD has high mortality, compounded by comorbid cardiovascular disease. We investigated two ECG markers, Cardiac Infarction Injury Score (CIIS) and P pulmonale, as prognostic tools for adverse cardiopulmonary events...
4.
Hashemi J, Lipson D, Arndt K, Davidson S, Kalhori A, Lunneberg K, et al.
Commun Earth Environ
. 2024 Sep;
5(1):473.
PMID: 39220210
Global atmospheric concentrations of nitrous oxide have been increasing over previous decades with emerging research suggesting the Arctic as a notable contributor. Thermokarst processes, increasing temperature, and changes in drainage...
5.
Han M, Criner G, Halpin D, Kerwin E, Tombs L, Lipson D, et al.
Chronic Obstr Pulm Dis
. 2023 Dec;
11(1):106-113.
PMID: 38081161
No abstract available.
6.
Kerwin E, Jones P, Bjermer L, Maltais F, Boucot I, Naya I, et al.
Chron Respir Dis
. 2023 Oct;
20:14799731231202257.
PMID: 37800633
This review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk....
7.
Mason C, Shahar S, Beals K, Kelley S, Lipson D, Swingley W, et al.
FEMS Microbiol Ecol
. 2023 Oct;
99(11).
PMID: 37791391
Restoring ecosystems requires the re-establishment of diverse soil microbial communities that drive critical ecosystem functions. In grasslands, restoration and management require the application of disturbances like fire and grazing. Disturbances...
8.
Wells J, Criner G, Halpin D, Han M, Jain R, Lange P, et al.
Chronic Obstr Pulm Dis
. 2022 Dec;
10(1):33-45.
PMID: 36516330
Background: In the InforMing the Pathway of COPD Treatment (IMPACT) trial, single-inhaler fluticasone furoate (FF) /umeclidinium (UMEC) /vilanterol (VI) significantly reduced severe exacerbation rates and all-cause mortality (ACM) risk versus...
9.
Bardsley S, Criner G, Halpin D, Han M, Hanania N, Hill D, et al.
Respir Med
. 2022 Dec;
205:107040.
PMID: 36470149
Background: Smoking is the major risk factor for chronic obstructive pulmonary disease (COPD). In IMPACT, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy significantly reduced moderate/severe exacerbation rates and improved lung function...
10.
Palmer B, Lawson D, Lipson D
Microb Ecol
. 2022 Nov;
85(3):1028-1044.
PMID: 36346444
Microbial communities are integral for ecosystem processes and their taxonomic composition and function may be altered by a disturbance such as fire. Biocrusts are composed of macroscopic and microscopic organisms...